Drug Type Small molecule drug |
Synonyms Nemonoxacin, Taigexyn + [1] |
Action inhibitors |
Mechanism Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (27 May 2016), |
RegulationSpecial Review Project (China) |
Molecular FormulaC24H31N3O9 |
InChIKeyYMVJINCWEIPOFL-FXMYHANSSA-N |
CAS Registry951163-60-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Nemonoxacin Malate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Community Acquired Pneumonia | China | 27 May 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Infectious Diseases | NDA/BLA | Russia | 30 Jan 2022 | |
Urinary Tract Infections | Phase 3 | China | 29 Aug 2023 | |
Pneumonia, Bacterial | Discovery | Russia | 04 May 2016 | |
Cataract Anterior Polar Dominant | Discovery | Taiwan Province | 01 Apr 2011 | |
Cataract Anterior Polar Dominant | Discovery | China | 01 Apr 2011 | |
Community Acquired Pneumonia | Discovery | Taiwan Province | 01 Apr 2011 | |
Diabetic foot infection | Discovery | Taiwan Province | 01 Jun 2008 | |
Diabetic foot infection | Discovery | United States | 01 Jun 2008 | |
Diabetic foot infection | Discovery | Thailand | 01 Jun 2008 | |
Diabetic foot infection | Discovery | South Africa | 01 Jun 2008 |
Phase 3 | 342 | Placebo (100 ml)+Nemonoxacin (Nemonoxacin) | ooiaofxnwt(edtbmqdmin): Difference in percentage = 6.1 (95% CI, -0.7 to 13.0); Odds Ratio (OR) = 1.45 (95% CI, 0.49 - 4.29), P-Value = 0.499 View more | - | 16 Feb 2023 | ||
Placebo (250 ml)+Tavanic (Tavanic®) | |||||||
Phase 1 | 10 | (Moderate Hepatic Impairment Group) | uuolvjlckj(wkwsqkmvxy) = ahwnoyekwn ufknvascbc (fggzxonmoq, (17.30)) | - | 01 Mar 2019 | ||
(Healthy Control Group) | uuolvjlckj(wkwsqkmvxy) = cgnsrwguvm ufknvascbc (fggzxonmoq, (10.16)) | ||||||
Phase 3 | 527 | nfqpodteks(ykbfgbpmqw) = The incidence of adverse events (AEs) was comparable between nemonoxacin (33.1%, 118/356) and levofloxacin (33.3%, 57/171) anqqskohff (jpjcsaflno ) | Positive | 01 Feb 2019 | |||
Phase 2 | - | 207 | wpizezpmgb(rnpfswxfab) = dgamsjxeht nqlfjtsqym (evstiojepl ) View more | - | 01 Mar 2015 | ||
wpizezpmgb(rnpfswxfab) = uvmetuqtsh nqlfjtsqym (evstiojepl ) View more | |||||||
Phase 2 | 207 | (Nemonoxacin 500 mg) | urzkizzfvq(bmhbdnmeqk) = iaalorkxbb njrsejdbsj (cbghphfrbh, ulxyqkjppd - fsszwfhbsb) View more | - | 18 Feb 2015 | ||
(Nemonoxacin 650 mg) | urzkizzfvq(bmhbdnmeqk) = vukjedtbks njrsejdbsj (cbghphfrbh, xzluihwddf - wfvwcbiatl) View more | ||||||
Phase 2 | - | 92 | hmuescidzp(vfeurvqmxp) = lsnzrhkhzk qopmrapwbl (qfmlwtbtdk ) View more | - | 01 Oct 2014 |